Hepatitis B control in jeopardy.

Area of Science:

• Public Health
• Vaccinology
• Infectious Diseases

Background:

• The United States Centers for Disease Control and Prevention (CDC) updated guidelines on universal neonatal vaccination.
• Shifts towards delaying the newborn Hepatitis B vaccine 'birth dose' are occurring.
• Rising vaccine hesitancy poses a significant risk to public health achievements.

Purpose of the Study:

• To analyze the impact of delaying the Hepatitis B vaccine beyond the first day of life.
• To discuss the potential effects on global health, economy, well-being, and development.
• To evaluate strategies for achieving the World Health Organization's (WHO) 2030 elimination goals for viral hepatitis.

Main Methods:

• Analysis of the implications of updated CDC guidelines on neonatal vaccination.
• Discussion of the potential consequences of delaying the initial Hepatitis B vaccine dose.
• Review of global health strategies in light of vaccine hesitancy and elimination targets.

Main Results:

• Delaying the Hepatitis B vaccine birth dose could jeopardize the WHO 2030 elimination goals.
• A potential public health reversal is possible, allowing Hepatitis B (HBV) to remain a global threat.
• Systemic screening gaps may be exacerbated by delayed vaccination schedules.

Conclusions:

• Maintaining the universal Hepatitis B vaccine birth-dose recommendation is the most reliable strategy.
• Universal birth-dose vaccination is essential for mitigating screening gaps.
• Achieving the global elimination of Hepatitis B and other viral hepatitis requires consistent birth-dose vaccination.